INTRODUCTION
Chimeric antigen receptor T (CAR-T) cells have become a new treatment modality in hematology. 1 Recently, two CD19-CAR-T cell products (tisagenlecleucel/Tisa-cel/Kymriah and axicabtagene ciloleucel/ Axi-cel/Yescarta) have been licensed for the treatment of different B cell malignancies.
1,2 CAR-T cell engraftment and expansion in vivo were shown to represent crucial parameters for efficacy of Axi-cel treatment. 3, 4 In particular, CAR-T cell peak concentrations and area under the curve in the first 28 days after Axi-cel infusion have been associated with long-term efficacy. 3, 4 Indeed, low initial CAR-T expansion seems to be associated with poorer outcome. However, additional data are necessary in order to adapt treatment protocols based on CAR-T engraftment. Unfortunately, diagnostic assays to quantitatively assess CAR-T cells in vivo are currently missing and thus are urgently needed.
Digital PCR (dPCR) represents an advancement of quantitative PCR, which is based on limiting-dilution and Poisson statistics. 5, 6 It is characterized by excellent sensitivity, specificity, and reproducibility, and is therefore considered an ideal tool for the quantitative determination of rare events, e.g., for MRD and chimerism diagnostics in hematology, 7, 8 but also the detection of gene-modified cells in vivo. 9 At our center, 16 patients have been treated with Axi-cel so far. In order to assess engraftment, expansion, and persistence of CAR-T cells, we aimed at establishing a dPCR assay for precise quantification of gene-modified cells in clinical samples. We here describe the development, testing, and clinical application of this assay.
RESULTS

Establishment and Testing of dPCR Assays
We first assessed dPCR performance for three primer/probe combinations (amplicons A, B, and C) on CAR-positive and -negative cells. As exemplarily illustrated for amplicon C, we observed ideal separation of negative and positive droplets ( Figure 1A ). Mixed DNA from 20 buffy coats as well as pre-infusion samples from patients were negative with the exclusion of one slightly positive PCR (0.07%) with amplicon A in a pre-infusion sample of patient #001; the sample was negative with both amplicons B and C.
To assess sensitivity and conformity, we performed duplex dPCRs on serial (half-log) dilutions of genomic DNA (gDNA) samples from one original product with a mean of approximately two vector copies per cell (i.e., both Axi-cel and REF [reference gene] were diploid) with all three assays resulting in almost perfect correlation of the two PCRs ( Figure 1B) . Notably, consistent positivity of the last (10-pg) samples (in all three assays) indicated a limit of detection (LoD) of 1 for both Axi-cel and REF. Indeed, 10 pg gDNA would be expected to contain a mean of three copies of any diploid gene or transgene. Considering Poisson distribution, the presence of a mean of three copies per tested volume unit would result in 95% of individual tests actually containing at least one copy, which in turn would be detectable by PCRs with an LoD of 1. At the same time, at the LoD level, independent Gaussian distribution of the two PCR targets (Axi-cel and REF) in individual samples would be expected to result in a loss of correlation and thus linearity between the two parameters. This is indeed the case as illustrated in Figures 1B and 1C . Furthermore, addition of each 100 ng of third-party gDNA (from healthy donors) to the samples of the dilution series did not impair sensitivity of the assay ( Figure 1C ).
Assay Reproducibility
To study reproducibility and potential inter-assay variations, we performed initial measurements in parallel using all three amplicons. We observed excellent coherence of the assays on tested Axi-cel products and patient samples (Table 1 ; Figure 2A ). Assay C was selected for further use. We next studied reproducibility of assay C on individual samples. To this end, we selected five samples from different patients, which represented a broad range of Axi-cel concentrations (approximately 0.3-13 cells/mL). For each sample, we performed three new independent dPCR runs ( Table 2 , runs 2-4) to assess potential inter-assay diversity. In addition, all dPCRs were performed in triplicates within these additional runs to test intra-run conformity. As shown in Table 2 , excellent reproducibility was found for all samples tested with the expected slightly higher variability at low cell levels due to normal distribution. 
Quantification of Axi-cel Vector Copies
Mean vector copy numbers (mVCNs) were first assessed in the Axicel products, using leftovers from the infusion bags. We found relatively high mVCNs in all samples with excellent inter-assay conformity (Table 1) .
Because mVCNs in the cell product had been determined for all cells (including non-transduced ones), we used Poisson statistics to define the mVCNs per transduced cell (see Materials and Methods). This approach is based on the idealized assumption that all cells were equally susceptible to transduction; it might therefore overestimate transduction rates and underestimate mVCNs in actually transduced cells. 11 However, it represents the best available approximation if gene transfer rates are unknown.
The calculated mVCNs per transduced cell (e.g., 2.36 for patient #003) were subsequently used to compute actual numbers of Axicel-positive cells using dPCR data for individual time points. For example, for patient #003, we measured 352 CAR and 8,620 REF 
Analysis of Patient Samples
During the initial method validation, patient samples were analyzed using the three dPCR assays in parallel, before we focused on assay C.
Because no product sample was available for patient #001, we assumed an mVCN per cell of 2 (corresponding to the lowest measured value in all products). Consequently, data obtained for this patient might overestimate actual numbers of Axi-cel cells in his blood. In any case, we saw very limited Axi-cel expansion and early loss of CAR-T cells ( Figure 2C ) corresponding to his clinical course of fast-progressing disease. Similar kinetics were found in patients #004, #005, #006, and #008 (two stable disease [SD] and two partial responses [PRs]; Figure 2C ; Table 1 ). In contrast, patients #003 (Figures 2A and 2B) , #007, #009, #010, and #011 ( Figure 2D ) showed the expected rapid CAR-T expansion with peaks above the median (11.2/mL) at days 7-12 accompanied by better clinical responses (two complete responses [CRs] and three PRs). Individual Axi-cel CAR-T kinetics are summarized in Figures 2C and 2D , and patient characteristics in Table 1 .
DISCUSSION
Recent approval of the two CD19-CAR-T cell products (Tisa-cel and Axi-cel) for the treatment of relapsed/refractory B cell malignancies has underlined the huge potential of targeted cellular Axi-cel peak/mL (day) 1 (34) 42 (11) 3 (26) 6 (14) 10 (9) 21 (7) 3 (12) 19 (10) 16 (9) 12 (12) CRS ( Data were obtained on Axi-cel infusion products. For the first seven patients, all three dPCR assays were used (A, B, and C). After finalizing evaluation, assay C was selected, and follow-up data were acquired with that assay only.
b Transduction rates were estimated using the Poisson formula based on the idealized assumption that all target cells were equally susceptible to transduction. 11 Actual transduction rates might thus be lower.
c Axi-cel mVCNs per transduced cell were calculated based on the estimated transduction rates. Actual mVCNs per transduced cell might therefore be higher. d CRS and ICANS grading were based on American Society for Transplantation and Cellular Therapy (ASTCT) Consensus criteria. 14 immunotherapies. Earlier clinical trials had identified efficient engraftment and expansion of CAR-T cells as a sine qua non for their efficacy, 3, 4 but the actual impact of engraftment kinetics on clinical efficacy of CAR-T cells and the risk for severe side effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) has remained largely obscure. These data are obviously essential in order to optimize treatment strategies in non-responders and patients with severe side effects. Therefore, the current lack of diagnostic assays to quantitatively assess CAR-T cells in vivo is quite surprising and needs to be overcome.
We have established dPCR-based assays combining excellent sensitivity, specificity, and reproducibility for follow-up diagnostics after Axi-cel treatment. All three assays target different regions of the CAR-vector construct and are therefore highly specific for Axi-cel products. At the end of the evaluation phase we chose one assay for further use. The LoD of 1 vector copy as established for this assay technically corresponds to a limit of quantification (LoQ) of 3; i.e., a sample containing a mean of three target copies in the test volume could be expected to become positive with a likelihood >95%.
In practical terms, if 100 ng gDNA (equivalent to approximately 15,000 cells or 30,000 haploid gene copies) will be tested, the given LoQ of 3 would translate into an actual sensitivity of 1 in 10,000 (3 in 30,000), or 0.01% (for any diploid gene). Because all tested Axi-Cel products contained R2 vector copies per cell, our routine testing of 120 ng DNA guaranteed a minimal sensitivity of 0.01%. Obviously, the sensitivity is even higher when the actual mean copy numbers of the CAR construct in transduced cells markedly excel 2, as in many of our cases. On the other hand, if gDNA isolated from whole blood containing large amounts of non-T cells would be used, the efficient sensitivity of the assay would be impaired. Therefore, we suggest using peripheral blood mononuclear cells (PBMCs) as starting material. Alternatively, the sensitivity might be increased by using larger gDNA amounts, but technical limitations might apply for a given dPCR system with regard to the maximally tolerable amount of gDNA. Also, the maximal number of quantifiable signals (using Poisson correction) is limited by the actual number of individual PCRs in a given dPCR device (e.g., approximately 20,000 droplets in the QX100/200). For the latter system, quantification at copy numbers >100,000 could be expected to be less precise. This would be relevant for the REF gene used in duplex PCRs as proposed here. Indeed, for a diploid gene the indicated upper limit of 100,000 copies would correspond to approximately 300 ng gDNA. Notably, using a Y chromosome-located haploid gene as reference allows doubling the DNA input in duplex dPCR. A further way to increase sensitivity is the use of sorted cell populations.
After thorough validation, we have applied one of the three assays for retrospective and prospective testing of patient samples. We performed diagnostic assays on gDNA isolated from PBMCs. In order to correctly determine the actual numbers of (Axi-cel) CAR-T cells, both the estimated vector copy number and the PBMC counts need to be taken into account. It cannot be excluded that mVCNs in transduced cells change over time. Although this is very unlikely in the early phase of polyclonal engraftment, it might become evident at later time points, when numbers of CAR-T cells (and thus also clones) will be reduced. However, the expected calculation error will be limited (e.g., a factor of 2 for a decrease in mVCNs from 4 to 2) and is therefore not expected to impact data significance, particularly at low CAR-T numbers, where presence is more relevant than numbers (e.g., 0.02 versus 0.01 Axi-cel CAR-T cells/mL).
The observed Axi-cel kinetics in vivo were in agreement with previously published results. 3, 4, 12 Interestingly, we found a trend for an association between more pronounced expansion and clinical responses. Indeed, the five patients early reaching CAR-T levels above the median peak level of 11.2/mL showed good 30-day clinical responses (two CR, two PRs, and one SD), whereas treatment efficacy was less pronounced (one progressive disease [PD], two SD, and two PRs) in the five patients for whom CAR-T peaks were below the median (peaking at 10 CAR-T cells, patient 6 with PR also had good T cell expansion close to the median). However, these clinical observations are preliminary and still require validation in a much larger prospective patient cohort.
In conclusion, we suppose that our novel dPCR assay for the sensitive detection of CAR-positive T cells will be very useful for centers performing CAR-T cell therapy with Axi-cel.
MATERIALS AND METHODS
Identification of Primer and Probes for dPCR
The complete cDNA sequence of the Axi-cel CAR construct was obtained by PCR and standard Sanger sequencing (eurofins Genomics, Ebersberg, Germany). PCR primers were selected by educated guess to bind the backbone of the g-retroviral vector in front of the CAR's cDNA (5 0 -ACCGCCCTCAAAGTAGACGG-3 0 ) and behind the CAR's cDNA in reverse orientation (5 0 -ACCTACAGGT GGGGTCTTTCA-3 0 ). The amplified PCR fragment was then sequenced using the same forward primer. Based on the obtained sequence, an internal primer was designed to sequence the second half of the CAR's cDNA (5 0 -CGGCCGCAATTGAAGTTATGT-3 0 ). The full-length sequence was found to be identical to the one previously published by Kochenderfer et al. 13 We used PrimerExpress_3.0.1 (Thermo Fischer) to design primers/ probes for three different amplicons (A, B, C) located in different regions of the CAR construct. To minimize cross-reactivity with human genes, we put the two primers of each amplicon on different functional domains of the CAR. The final primer/probe combination (C) is available from Bio-Rad (Foster City, CA, USA) as an Expert Design Assay (catalog [Cat.] number dEXD45718942).
gDNA and dPCR gDNA was prepared from unseparated peripheral blood (PB) or PBMCs with QIA-Amp Blood Kit (QIAGEN, Hilden, Germany) following the manufacturer's protocols. 7 dPCR was carried out with the QX100 Droplet-Digital PCR System (Bio-Rad) as described previously. 7 To assess numbers of analyzed genome equivalents and ensure sample quality, we concomitantly amplified CAR and REF sequences using differently labeled 
Calculations and Statistics
To assess mVCNs in a given Axi-cel product, we performed duplex dPCRs with Axi-Cel and REF primers, and copy numbers were calculated for the two amplicons using QuantaSoft_v.1.7 software. Whereas REF copy numbers provided information on the absolute numbers of alleles (and thus cells) tested, the Axi-cel dPCR determined the absolute number of vector copies in this very sample. To define the actual mVCNs per transduced cells, it had to be taken in account that the cellular product contained both transduced and non-transduced cells. Provided that all cells are equally susceptible to transduction by the used retroviral vector, Poisson statistics can be applied to determine the transduction rate based on the measured vector copy number. 11 Under this assumption, a mean copy number of, for example, 2 in an Axicel cell product corresponds to a transduction rate of 86.5%. 11 Consequently, in such case, transduced cells contain a mean of 2.31 (2/0.865) copies.
Correlation coefficients were determined using two-tailed Pearson statistics with a confidence interval of 95%. Statistical analyses were made with GraphPad Prism (San Diego, CA, USA).
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